

Supplemental Table S4. The grading of alanine aminotransferase (ALT) during the 12-month treatment period by the level of baseline liver function tests (LFTs) and the interaction with treatment assignment (GTE or Placebo), the Minnesota Green Tea Trial, 2009-2015

	Placebo	GTE	<i>P</i> ^a	<i>Pint</i> ^a
Participants with all LFTs below ULN at baseline	487	490		
Highest level of ALT during the intervention period				
Normal, Grade 0 (<75 U/L)	480	451	<0.0001	
Abnormal (≥75U/L)				
Grade 1 (75-150 U/L)	7	23		
Grade 2 or above (>150 U/L)	0	16		0.41
Participants with any LFT above ULN ^b at baseline	21	23		
Highest level of ALT during the intervention period				
Normal, Grade 0 (<75 U/L)	19	18	0.27	
Abnormal (≥75U/L)				
Grade 1 (75-150 U/L)	2	4		
Grade 2 or above (>150-300 U/L)	0	1		

^a 2-sided *P* values were derived from unconditional logistic regression model. ULN, upper limit of normal.

^b ULN for all 4 liver function tests (LFTs) including alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphate (AKP), and total bilirubin, were defined in Supplemental Table S1.